form8-k.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15 (d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): September 18,
2005
SANGUI
BIOTECH INTERNATIONAL, INC.
(Exact
Name of Registrant as Specified in Its Charter)
Colorado
(State
or
Other Jurisdiction of Incorporation)
000-21271
84-1330732
(Commission
File
Number) (IRS
Employer Identification No.)
Alfred-Herrhausen-Str.
44, 58455 Witten, Germany
(Address
of Principal Executive Offices) (Zip Code)
011-49-2302-915-204
(Registrant's
Telephone Number, Including Area Code)
N/A
(Former
Name or Former Address, if Changed Since Last Report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
Item
4.01. Changes in Registrant’s Certifying Accountant.
On
September 18, 2007, the Board of
Directors of Sangui Biotech International, Inc. (“Company”) approved the
engagement of the accounting firm of Moore & Associates, Chartered (“Moore
& Associates”) as its independent registered public accounting firm
effective immediately. In connection with its choice of Moore &
Associates, the Directors terminated HJ & Associates, LLC (“HJ &
Associates”) who had previously been the Company’s independent registered public
accounting firm.
The
change in independent accountants
did not result from any dissatisfaction with the quality of professional
services rendered by HJ & Associates.
The
audit reports of HJ &
Associates on the Company’s financial statements for the fiscal years ended June
30, 2004 and 2005 did not contain an adverse opinion or disclaimer of opinion
and were not qualified or modified as to uncertainty, audit scope or accounting
principles.
In
connection with the audits of the
fiscal years ended June 30, 2004 and 2005 and the subsequent interim period
prior to such dismissal, there were (1) no disagreements with HJ &
Associates on any matter of accounting principles or practices, financial
statement disclosure, or auditing scope or procedure, which disagreements,
if
not resolved to the satisfaction of HJ & Associates, would have caused them
to make reference thereto in their reports on the financial statements for
such
periods to the subject matter of the disagreement, and (2) no reportable
events.
HJ
&
Associates
has furnished the
Company with a letter addressed to the Securities and Exchange Commission
stating whether it agrees with the above statements. A copy of that
letter is included as exhibit 16.1 to this Report on Form 8-K.
Item
8.01 Press Release
On
September 21, 2007, the Company
issued a Press Release announcing the change in Auditors. A copy of the release
is included as exhibit 99.1 to this Report on Form 8-K.
Item
9.01. Financial Statements and Exhibits.
|
Exhibit No.
|
|
Description
|
|
16.1
|
|
Letter
re Change in Certifying Accountant
|
| |
|
|
99.1
|
|
Press
Release
|
SIGNATURES
Pursuant
to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report
to
be signed on its behalf by the undersigned hereunto duly
authorized.
Sangui
Biotech International,
Inc.
Date:
September 21,
2006
/s/ Wolfgang Barnikol
_______________________________________
By:
Wolfgang Barnikol
Its: President,
CEO and CFO